This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Hypervalinemia and Hyperleucine-isoleucinemia고발린혈증 / 고류신-이소류신혈증

Contents and key points
ItemDetails
A. Classification codesICD-10: E71.1 (other disorders of branched-chain amino acid metabolism) | Special Copayment Reduction: V117 (ultra-rare disease, copayment exempt)
B. SynonymsHypervalinemia, hyperleucine-isoleucinemia, HVLI, branched-chain amino acid transaminase 2 deficiency (BCAT2 deficiency), branched-chain amino acid metabolism disorder, OMIM #618850
C. Adult onsetLikelihood of first presentation in adulthood: possible — many cases are diagnosed in the neonatal period or infancy, but in mild phenotypes, cases have been reported in which headache, memory impairment, and white matter abnormalities are first identified in adulthood. Plasma amino acid analysis is needed when differentiating unexplained leukoencephalopathy in adult neurology.
1. History1960s first report of hypervalinemia → 2015 Wang et al. identify BCAT2 gene variants as the cause → 2025 publication of a systematic literature review.
2. CausesLoss of function of mitochondrial branched-chain amino acid transaminase 2 (BCAT2) due to pathogenic variants in the BCAT2 gene (19q13). Deficiency of an enzyme dependent on the cofactor pyridoxal 5'-phosphate (PLP, vitamin B6).
3. GeneticsAutosomal recessive inheritance. BCAT2 gene 19q13.33. Homozygous or compound heterozygous variants. Very few reported cases.
4. General epidemiologyFewer than 10 confirmed cases worldwide. Ultra-rare. Ethnic or regional predilection unclear. No or extremely few reported cases in Korea.
5. PathophysiologyBCAT2 enzyme deficiency → accumulation of plasma valine, leucine, and isoleucine → toxic effects on cerebral white matter. Unlike maple syrup urine disease (MSUD), branched-chain keto acids are normal.
6. SymptomsHeadache, memory decline, intellectual disability, growth retardation, poor feeding, muscle weakness, vomiting, developmental delay.
7. SignsSymmetric white matter signal abnormalities on brain MRI, markedly elevated plasma valine, leucine, and isoleucine, normal branched-chain keto acids, normal alloisoleucine.
8. ScreeningNewborn tandem mass spectrometry (MS/MS) — confirmation of a pattern of elevated valine, leucine, and isoleucine on plasma amino acid analysis.
9. DiagnosisDetailed plasma amino acid analysis + urine organic acids + BCAT2 gene analysis. Exclusion of MSUD is essential.
10. TreatmentHigh-dose vitamin B6 (PLP supplementation), branched-chain amino acid-restricted diet, glucose supplementation in the acute phase, symptomatic neuroprotective treatment.
11. PrognosisWhite matter lesions may improve with early diagnosis and vitamin B6 treatment. Neurological improvement following reduction of valine levels has been reported.
12. PreventionGenetic testing and genetic counseling, prenatal diagnosis (amniocentesis, CVS), expansion of newborn screening, family carrier testing.
13. ReferencesWang et al. J Inherit Metab Dis. 2015 (PMID 25653144) … and 9 other papers

1. History

Hypervalinemia was first clinically described in the early 1960s in infants with markedly elevated plasma valine concentrations. Early reports presented cases of infants with intellectual disability, growth retardation, and poor feeding in whom plasma amino acid analysis showed selectively elevated valine, but at that time the exact enzyme defect and molecular mechanism had not been identified. Valine is one of the three branched-chain amino acids (BCAA) and, together with leucine and isoleucine, is an essential amino acid with a key role in protein synthesis and energy metabolism.

Reports of hyperleucine-isoleucinemia appeared around the same time, but it took decades to establish that the molecular cause of these disorders is an independent entity distinct from maple syrup urine disease (MSUD). The key to differentiation is that in MSUD, deficiency of the branched-chain α-keto acid dehydrogenase (BCKD) complex raises both branched-chain amino acids and branched-chain keto acids, whereas in hypervalinemia/hyperleucine-isoleucinemia, branched-chain keto acids and alloisoleucine remain at normal levels.

The decisive molecular identification came in a 2015 study by Wang et al. published in the Journal of Inherited Metabolic Disease. They found compound heterozygous variants in the BCAT2 gene (branched-chain amino acid aminotransferase 2) in a patient with hypervalinemia and hyperleucine-isoleucinemia and showed that loss of function of the mitochondrial BCAA transaminase (BCAT2) encoded by this gene is the cause of the disease. BCAT2 is an enzyme that uses vitamin B6 (pyridoxal 5'-phosphate, PLP) as a cofactor and catalyzes the transamination reaction, the first step in BCAA degradation. This discovery is significant not only as a molecular identification but also because it opened a clinical path to lowering blood BCAA levels and improving neurological symptoms through vitamin B6 supplementation.

In 2025, the first systematic review and case series on BCAT2 deficiency was published, comprehensively analyzing about 8 cases reported worldwide. This study provided a more systematic understanding of the phenotypic spectrum, neuroimaging findings, and treatment response of BCAT2 deficiency. With only a very small number of confirmed cases reported, this disease is currently classified as one of the rarest inherited metabolic diseases, and reports from Korea have not yet been officially confirmed. Additional diagnosed cases are expected to increase with expanded newborn screening programs and wider use of whole-genome sequencing (WGS).


2. Causes

The cause of hypervalinemia/hyperleucine-isoleucinemia (HVLI) is deficiency of the mitochondrial branched-chain amino acid aminotransferase 2 (BCAT2) enzyme due to pathogenic variants in the BCAT2 gene. The BCAT2 gene is located on the long arm of chromosome 19 (19q13.33) and encodes the mitochondrial form of the two BCAT isozymes in humans. Unlike cytoplasmic BCAT1 (expressed mainly in the brain and peripheral tissues), BCAT2 is expressed systemically, in the liver, muscle, adipose tissue, etc., and handles the main pathway of BCAA catabolism.

The BCAT2 enzyme is a PLP-dependent aminotransferase that requires pyridoxal 5'-phosphate (pyridoxal-5-phosphate, PLP), the active form of vitamin B6, as an essential cofactor. The main reaction of the enzyme is reversible transamination of valine, leucine, and isoleucine to α-ketoisovalerate, α-ketoisocaproate, and α-keto-β-methylvalerate, respectively. When this reaction is blocked, the three BCAAs accumulate in the blood. The fundamental difference from MSUD is that in BCAT2 deficiency, the first step of the BCAA degradation pathway is blocked, so the downstream products, branched-chain α-keto acids (BCKAs) and allo-isoleucine, remain at normal levels.

Pathogenic BCAT2 variants act by reducing the enzyme protein's ability to bind its cofactor (PLP) or by reducing protein stability and catalytic activity. In the patient first reported by Wang et al. (2015), compound heterozygous missense variants were identified, and functional studies demonstrated markedly reduced BCAT2 enzyme activity compared with the wild type. Homozygous or compound heterozygous pathogenic variants were also identified in subsequently reported cases. A pharmacogenetic response was observed in which residual enzyme activity increased and plasma BCAA concentrations decreased with PLP supplementation (high-dose vitamin B6), suggesting that some BCAT2 variants are cofactor-responsive mutations.

Variants of the BCAT1 isozyme (cytoplasmic form, OMIM *113520) can cause a distinct neurological phenotype and differ from BCAT2 deficiency in tissue expression pattern and clinical presentation. The role of environmental factors in the development of HVLI is unclear, but plasma BCAA accumulation may intensify with a high-protein diet or in catabolic states, so dietary protein intake may influence the clinical presentation. The phenotypic heterogeneity of the disease is understood to arise from differences in the type of variant, the degree of residual enzyme activity, and PLP responsiveness.


3. Genetics

HVLI follows an autosomal recessive mode of inheritance. Patients must have pathogenic variants in both alleles of the BCAT2 gene, manifesting in a homozygous or compound heterozygous state. Carriers (heterozygous carriers) generally have a normal phenotype, and the probability of a child of two carrier parents being affected is 25%.

The BCAT2 gene is located near the terminal end of the long arm of chromosome 19 (19q13.33), spans about 25 kb in total, and consists of 11 exons. The encoded protein has a homodimer structure of 386 amino acids, with a PLP-binding site in each monomer. The three-dimensional structure of the human BCAT2 protein has been determined crystallographically, and structure-function studies of PLP-binding residues and substrate-binding sites have been carried out. The number of known pathogenic variants is very limited (about 8 reported worldwide), and missense and nonsense variants have been reported. No specific founder mutation or variant hotspot has yet been clearly identified, but judgment is limited by the small number of cases.

BCAT2 gene testing is performed by next-generation sequencing (NGS)-based metabolic disease panels, whole-exome sequencing (WES), or whole-genome sequencing (WGS). When only a single pathogenic variant is found, multiplex ligation-dependent probe amplification (MLPA) or comparative genomic hybridization (CGH array) should be additionally considered to check for exon deletions or duplications. The pathogenicity of variants found is assessed according to American College of Medical Genetics and Genomics (ACMG) criteria, but because reported cases are extremely few, it is important to integrate the results of functional studies (enzyme activity measurement, cellular expression systems) into the interpretation.

When a BCAT2 variant has been identified in the family, prenatal genetic testing is possible by analysis of fetal DNA obtained by chorionic villus sampling (CVS, 11–14 weeks of gestation) or amniocentesis (15–20 weeks of gestation). Preimplantation genetic testing (PGT), combined with in vitro fertilization, is technically possible as a method of preventing implantation of affected embryos. When the parents are confirmed carriers, performing early metabolic screening including plasma amino acid analysis (measurement of valine, leucine, and isoleucine) in the newborn allows diagnosis before symptom onset and early initiation of treatment.


4. General epidemiology

Hypervalinemia/hyperleucine-isoleucinemia (HVLI, BCAT2 deficiency) is an ultra-rare inherited metabolic disease for which only fewer than about 8 confirmed cases have been reported in the literature worldwide to date. The exact prevalence and incidence are unknown, and the number of cases to date is so small that statistical estimation itself is difficult. The systematic review published in 2025 also analyzed 8 cases worldwide, reflecting that recognition and diagnosis of this disease in the medical community began relatively recently.

Data on ethnic or regional predilection are currently lacking. The first reported patient was Chinese, described in the study by Wang et al. (2015). Patients of other ethnic backgrounds have since been reported, but no specific founder variant or ethnic clustering has yet been identified. It is presumed that a considerable number of cases are undiagnosed or misdiagnosed as other diseases (MSUD, nonspecific intellectual disability, etc.). In screening programs using newborn tandem mass spectrometry (MS/MS), elevated plasma valine and leucine/isoleucine may be markers of this disease, but most current standard newborn screening panels lack an algorithm to distinguish and follow this specific pattern as BCAT2 deficiency.

There have been no or only very few official reports in Korea to date. However, with the expansion of newborn screening and wider use of NGS-based diagnosis in Korea, domestic diagnosed cases may be identified in the future. In Health Insurance Review & Assessment Service (HIRA) data, cases with confirmed BCAT2 deficiency among patients registered under code E71.1 have not yet been clearly separated and reported. Because this disease qualifies for Special Copayment Reduction as an ultra-rare disease (V117) under the Rare Disease Management Act, copayment exemption is provided upon confirmed diagnosis.

With improving diagnostic capacity for rare inherited metabolic diseases worldwide (increased access to WES/WGS, reclassification of vitamin B6-responsive disorders), awareness and diagnostic rates of BCAT2 deficiency are expected to gradually increase. In particular, a differential diagnosis system that includes BCAT2 analysis needs to be established for cases of unexplained leukoencephalopathy or neurodegeneration accompanied by elevated branched-chain amino acids.


5. Pathophysiology

The BCAT2 enzyme catalyzes the first step of branched-chain amino acid (BCAA) catabolism within mitochondria. Specifically, it is the transamination of valine to α-ketoisovalerate (KIV), leucine to α-ketoisocaproate (KIC), and isoleucine to α-keto-β-methylvalerate (KMV). In this reaction, glutamate acts as a cosubstrate that transfers the amino group to α-ketoglutarate, and PLP functions as the reaction mediator. In BCAT2 deficiency, this pathway is blocked, and the three BCAAs accumulate in plasma and tissues.

The decisive difference from MSUD is that in BCAT2 deficiency, the branched-chain α-keto acid dehydrogenase (BCKD) complex located downstream in the BCAA catabolic pathway is preserved. Therefore, branched-chain keto acid (BCKA) and alloisoleucine levels in plasma and urine are normal, and the maple syrup odor characteristic of MSUD does not occur. This feature is the key indicator distinguishing the two diseases clinically and biochemically.

Accumulated BCAAs, particularly high concentrations of valine and leucine, exert toxic effects on the brain through several pathways. First, excess BCAAs competitively inhibit brain uptake of other amino acids (especially the aromatic amino acids tryptophan, phenylalanine, and tyrosine) via the large neutral amino acid transporter (LAT1, SLC7A5/SLC3A2) of the blood-brain barrier (BBB). As a result, brain concentrations of precursors for neurotransmitter synthesis such as serotonin and dopamine decrease. Second, high concentrations of valine may affect protein synthesis and the mTORC1 signaling pathway, impairing neuronal growth, differentiation, and survival. Third, excessive mTOR activation by leucine may contribute to neurotoxicity through mechanisms such as inhibition of autophagy, endoplasmic reticulum stress, and neuroinflammation.

The mechanism of the neuroimaging finding of symmetric white matter signal abnormality is explained by impaired myelin formation or breakdown of already formed myelin. Because BCAAs play an important role in white matter energy metabolism, precursor metabolic imbalance may lead to oligodendrocyte dysfunction and myelination defects. The course in which MRI lesions improve as residual BCAT2 enzyme activity increases and plasma BCAA levels decrease with vitamin B6 supplementation suggests that this mechanism is reversible.


6. Symptoms

Because the number of reported cases is extremely small, the phenotypic spectrum of the clinical symptoms of HVLI (BCAT2 deficiency) is not fully defined, but taken together, existing reports show a variety of symptoms mainly involving the nervous system and overall development. Symptom severity ranges from mild neurocognitive abnormalities to severe intellectual disability depending on the type of variant and residual enzyme activity.

Neurocognitive symptoms: headache is commonly reported in adult and older child patients. Memory decline and cognitive dysfunction may accompany it, and intellectual disability and developmental delay are observed in some patients. Learning disabilities and poor concentration may appear, so in school-age children the condition is sometimes first recognized as attention deficit and learning problems.

Neurological symptoms: muscle weakness and hypotonia may appear in infancy and early childhood. Motor developmental delay may manifest as delayed onset of walking. Gait abnormalities (ataxia or spasticity) have been reported in some cases. Seizures may accompany severe white matter abnormalities.

Gastrointestinal and systemic symptoms: in neonatal and infant patients, feeding difficulties, vomiting, and growth retardation may appear as initial symptoms. Poor weight gain and nonspecific infant failure to thrive have been reported. Because valine, leucine, and isoleucine rise more after a protein-rich diet or in catabolic states (infection, surgery, fasting), a pattern of symptoms worsening or appearing acutely in such situations may be observed.

Adult-onset symptoms: in patients with a mild phenotype, there are cases in which headache and memory decline first appear in adulthood, or the diagnosis is made when visiting a neurologist with unexplained neurological symptoms as the chief complaint. When recurrent headache, cognitive decline, and unexplained white matter abnormalities are present in an adult, BCAT2 deficiency should be included in the differential diagnosis.


7. Signs

Biochemical signs — plasma amino acids: the most characteristic and diagnostic laboratory finding of HVLI is marked elevation of plasma valine, leucine, and isoleucine concentrations. Valine tends to be particularly prominently elevated; in the report by Wang et al. (2015), values reaching more than 5 times the upper limit of normal (1754 μmol/L, normal range 100–350 μmol/L) were observed. Leucine and isoleucine also greatly exceed the normal range. However, unlike MSUD, plasma alloisoleucine is at normal levels, and there is no elevation of branched-chain keto acids (BCKAs). This pattern is the decisive criterion for differentiating BCAT2 deficiency from MSUD.

Urine organic acids: branched-chain keto acids (α-ketoisovalerate, α-ketoisocaproate, α-keto-β-methylvalerate) and their hydroxy derivatives in urine are normal or only slightly elevated. It is important that the pronounced branched-chain ketonuria observed in MSUD is absent.

Neuroimaging findings: symmetric white matter signal abnormality is observed on brain magnetic resonance imaging (MRI). It is characterized by symmetric hyperintense lesions in the subcortical and deep white matter on T2-weighted and FLAIR images. The internal capsule, the area around the basal ganglia, and the centrum semiovale may be involved. Reduction or disappearance of MRI lesions after vitamin B6 treatment has been reported, so imaging findings are also used to monitor treatment response.

Enzyme activity measurement: BCAT2 enzyme activity can be measured in lymphocytes or skin fibroblasts, and patients show markedly reduced activity. If residual activity increases with additional PLP, the variant is classified as PLP-responsive (cofactor-responsive variant), which is useful for predicting response to vitamin B6 treatment. Along with genetic analysis, functional studies (intracellular expression and enzyme assays) are used as an aid in determining variant pathogenicity.


8. Screening

A standardized, specific newborn screening protocol for HVLI has not yet been established. However, expanded screening based on newborn tandem mass spectrometry (MS/MS) provides potential markers. When combined elevation of valine and leucine/isoleucine concentrations is detected on plasma amino acid analysis, BCAT2 deficiency should be included in the differential along with MSUD.

When BCAA elevation is found on newborn screening, the next-step differential testing flow is as follows. Step 1: detailed quantitative plasma amino acid analysis (separate quantification of valine, leucine, isoleucine, and alloisoleucine). Step 2: urine organic acid analysis (checking for elevated branched-chain keto acids). Step 3: if the pattern is normal alloisoleucine, normal BCKAs, and elevated BCAAs only, consider the possibility of BCAT2 deficiency. Step 4: confirmation by BCAT2 gene analysis or enzyme activity measurement. The key point is that even if MSUD criteria screening is positive, BCAT2 deficiency must be separately considered when alloisoleucine and BCKAs are normal.

BCAT2 deficiency is not currently included as an explicit item in Korea's newborn screening panel (which includes 20 or more standard conditions). However, when elevated valine is detected on expanded screening including amino acid analysis, referral to a specialized metabolic disease center and additional differential testing are needed. In at-risk families with a family history (a sibling already diagnosed or both parents confirmed as carriers), early diagnosis is possible by measuring plasma amino acids immediately after birth.


9. Diagnosis

Definitive diagnosis of HVLI (BCAT2 deficiency) follows the stepwise approach below. Biochemical diagnosis is primary, and molecular genetic confirmation is the final step.

Detailed plasma amino acid analysis: the key findings are marked elevation of valine, leucine, and isoleucine (each ≥2 times the upper limit of normal) with normal alloisoleucine. Plasma amino acid profile analysis using ion-exchange chromatography (IEC) or tandem mass spectrometry (MS/MS) is the standard method. Because whether alloisoleucine is normal is the key criterion for excluding MSUD, an analytical method that accurately separates and quantifies this item must be used.

Urine organic acid analysis: gas chromatography-mass spectrometry (GC-MS)-based organic acid analysis confirms the absence of marked elevation of branched-chain keto acids (BCKAs). In MSUD, α-ketoisovalerate, α-ketoisocaproate, and α-keto-β-methylvalerate are clearly elevated, but in BCAT2 deficiency they are normal or mildly elevated.

BCAT2 gene analysis: pathogenic variants in the BCAT2 gene (19q13.33) are identified by NGS-based rare metabolic disease panels, whole-exome sequencing (WES), or whole-genome sequencing (WGS). When only a single variant is found, exon-level deletions should be excluded by MLPA or chromosomal microarray. Parental testing and segregation analysis are performed to assess the pathogenicity of variants found.

Confirmation of enzyme activity: where clinically available, BCAT2 enzyme activity can be measured in lymphocytes or cultured skin fibroblasts. Checking the change in enzyme activity before and after PLP addition allows determination of whether the variant is PLP-responsive and prediction of response to vitamin B6 treatment. However, this test can only be performed in specialized biochemical laboratories.

Neuroimaging: brain MRI (including T1, T2, FLAIR, DWI) is performed at diagnosis and to assess treatment response. The distribution and extent of symmetric white matter signal abnormalities are documented. MRS (magnetic resonance spectroscopy) has additional value in assessing metabolic abnormalities within lesions.


10. Treatment

Treatment of HVLI (BCAT2 deficiency) centers on vitamin B6 (pyridoxine/pyridoxal-5-phosphate) supplementation and a branched-chain amino acid-restricted diet. Treatment experience with this disease is limited to very few cases worldwide, so standardized treatment guidelines have not yet been established, but these are the approaches for which effective treatment responses were confirmed in existing reports.

High-dose vitamin B6 supplementation: because BCAT2 is a PLP-dependent enzyme, enhancing residual enzyme activity through PLP supplementation is the core of treatment. In the initial report by Wang et al. (2015), intravenous pyridoxine 100 mg/day for 5 days reduced plasma valine from 1754 μmol/L to 1020 μmol/L. Subsequently, sustained reduction of BCAA levels and improvement of MRI lesions were reported with oral high-dose vitamin B6 maintenance therapy. There is no standard for the appropriate dose, route, or duration, but adjustments are made while monitoring clinical response (plasma BCAA levels, neurological symptoms, MRI findings). Because sensory neuropathy may occur as an adverse effect of long-term high-dose vitamin B6, periodic neurological monitoring is needed.

Branched-chain amino acid-restricted diet: restricting dietary intake of valine, leucine, and isoleucine to lower blood concentrations is an adjunctive pillar of treatment. However, because BCAAs are essential amino acids, intake must be adjusted to meet physiological requirements, and in infants and growing children BCAA intake is monitored while maintaining appropriate protein intake. Special amino acid formulas for MSUD (formulations excluding or restricting valine, leucine, and isoleucine) can be used. The diet is adjusted through regular plasma amino acid monitoring to maintain appropriate levels (valine, leucine, and isoleucine within the normal range).

Acute-phase treatment: BCAAs may rise sharply in catabolic situations such as infection, surgery, or fasting. In such cases, protein catabolism is suppressed through oral or intravenous glucose, and adequate fluids and energy supplementation are maintained. In severe acute metabolic crises, inpatient intensive care with nutritional support is needed.

Management of neurological symptoms: anticonvulsants are used when seizures are present. Developmental delay and intellectual disability require early rehabilitation (physical therapy, occupational therapy, speech therapy) and special education support. For headache and cognitive dysfunction, symptomatic treatment is combined with underlying metabolic treatment.


11. Prognosis

Systematic data on the prognosis of HVLI are insufficient because the number of cases is extremely limited, but cases reported to date have confirmed that substantial clinical improvement is possible with early diagnosis and treatment. The most important factors affecting prognosis are the timing of diagnosis, whether the variant is vitamin B6-responsive, and the degree of branched-chain amino acid control.

In patients with PLP-responsive variants that respond to vitamin B6 treatment, an improving course with decreasing plasma BCAA concentrations and improving MRI white matter lesions has been reported. In the case of Wang et al., a course of decreased headache and improved cognitive function was observed after treatment initiation. In contrast, with variants with no or low PLP responsiveness, or when diagnosis is delayed, neurological damage may progress irreversibly.

An important consideration in long-term prognosis is sustained metabolic control. Because neurological damage may accumulate if plasma valine, leucine, and isoleucine remain persistently very high, long-term dietary management and maintenance of vitamin B6 supplementation are essential for preserving neurological outcome. Acute deterioration and metabolic crises during catabolic episodes (infection, surgery) can be minimized with prompt treatment. There are currently almost no long-term follow-up data into adulthood, so long-term registry studies are needed to understand the lifelong natural history of this disease. The effect of early intervention on learning, language, and cognitive function is presumed to be a major determinant of long-term functional outcome.


12. Prevention

Primary prevention of HVLI is achieved through carrier identification and genetic counseling. When a patient with BCAT2 deficiency is identified in a family, BCAT2 gene testing is performed in family members including parents and siblings to determine carrier status. When both parents are carriers, the risk of an affected child (25%) and prenatal diagnosis options are fully explained through genetic counseling at the pregnancy planning stage.

For prenatal diagnosis of a known familial variant, fetal DNA is obtained by chorionic villus sampling (CVS, 11–14 weeks of gestation) or amniocentesis (15–20 weeks of gestation), and BCAT2 gene analysis determines whether the fetus is affected. Preimplantation genetic testing (PGT-M), combined with in vitro fertilization (IVF), is technically possible as a method of preventing uterine implantation of affected embryos. Plasma amino acid analysis is performed immediately after birth in all newborns of confirmed carrier parents to enable early diagnosis and initiation of treatment.

Expanding newborn screening is a population-level prevention strategy that enables asymptomatic early diagnosis of this disease. It is necessary to add a BCAT2 deficiency-specific biomarker algorithm to current standard newborn screening panels, or to develop protocols that include a BCAT2 deficiency differentiation pathway when a pattern of combined valine/leucine/isoleucine elevation is detected through expanded screening. After diagnosis, treatment response is assessed and complications are detected early through regular follow-up (plasma amino acid monitoring, neurocognitive assessment, MRI follow-up).


13. References

  1. Wang XL, et al. Hypervalinemia and hyperleucine-isoleucinemia caused by mutations in the branched-chain-amino-acid aminotransferase gene. J Inherit Metab Dis. 2015;38(5):873-879. PMID: 25653144
  2. Yap S, et al. Branched-chain amino acid transferase 2 (BCAT2) deficiency: A case series and systematic review. PMC. 2025. PMC12853772.
  3. Blackburn PR, et al. Maple syrup urine disease: mechanisms and management. Appl Clin Genet. 2017;10:57-66. PMID: 28919799
  4. OMIM Entry #618850. HYPERVALINEMIA AND HYPERLEUCINE-ISOLEUCINEMIA; HVLI. Available at: https://www.omim.org/entry/618850
  5. Sweatt AJ, et al. Branched-chain amino acid catabolism: unique segregation of pathway enzymes in organ systems and peripheral nerves. Am J Physiol Endocrinol Metab. 2004;286(1):E64-76. PMID: 14519601
  6. Burrage LC, et al. Branched-chain amino acid metabolism: from rare Mendelian diseases to more common disorders. Hum Mol Genet. 2014;23(R1):R1-8. PMID: 24651065
  7. Homanics GE, et al. Pyridoxal phosphate-dependent enzymes and genetic epilepsy. Ann Neurol. 2012;71(5):579-586. PMID: 22555583
  8. Faber KN, et al. Transport of amino acids across the blood-brain barrier via the large neutral amino acid transporter (LAT1). J Neurochem. 2001;76(3):617-626. PMID: 11158234
  9. Strauss KA, et al. Classical maple syrup urine disease and brain development: principles of management and formula design. Mol Genet Metab. 2010;99(4):333-345. PMID: 20083404
  10. Fernandez-Caggiano M, et al. Leucine and metabolism: from nutrient sensing to disease. J Nutr Biochem. 2021;88:108551. PMID: 33246163